Celularity guides Q4 2023 revenue ~$12.1M, Q1 2024 revenue ~$14.8M

Celularity Inc

2024-Q1 EPS reported -$1.03 revenue$14,681,000

Preliminary Q4 2023 net revenue ~$12.1M from biomaterial product sales and biobanking services.
Preliminary Q1 2024 net revenue ~$14.8M from the same segments, up ~22% sequentially.
Full-year 2023 and Q1 2024 financials not yet finalized; subject to audit/review adjustments.
Company hosted an Investor & R&D Day on May 21, 2024, with presentation posted on IR website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.